PTC Therapeutics approved stock options for 51,270 shares and 37,995 restricted stock units (RSUs) to 37 new employees as part of their compensation. These inducement grants, approved on September 22, 2026, are designed to encourage employment acceptance and vest over four years. The stock options have a 10-year term with an exercise price of $65.96 per share, matching the stock's closing price on the grant date. This move supports PTC's strategy to attract talent while advancing its mission to develop treatments for rare disorders.
PTC Therapeutics inducement grants were announced recently, with Pluang market data as of Sep 26, 2026 03:22 WIB showing that out of 100 priced Health-sector US stocks, 53 rose and 47 fell. Notable movers include HRTX at USD 0.30 with a 3.34% increase and a typical hold time of 34 days, DNA at USD 10.57 up 3.12% with a 9-day hold time, and FLNA at USD 0.75 down 2.95% with a 37-day hold time. The most notable figure is HRTX’s 58% buy order activity on Pluang.
Masonglory Limited's shares soared over 300% following its share swap deal to acquire a 20% stake in an Austrian construction firm, expanding its business scope. INLIF Limited gained about 74% after reporting strong first-half fiscal 2026 results wit...
Gerdau S.A., a leading steel producer in the Americas, demonstrates solid financial health with a Piotroski Score of 8, indicating strong profitability, leverage, liquidity, and efficiency. Despite exposure to steel market volatility, analysts remain...
Kodiak Sciences will report topline results from its Phase 3 DAYBREAK study on September 28, 2026. The study evaluates two treatments, Zenkuda™ and KSI-501, for wet age-related macular degeneration (AMD). These drugs target a significant $15 billion ...
Zano, a privacy-focused blockchain, paused all economic activity after finding a bug that allowed unauthorized coin creation through its Gateway Addresses feature. This flaw undermines Zano's fixed supply model, prompting a planned rollback of about ...
Nvidia is still recommended as a Buy, even considering potential risks from AI safety debates and regulatory slowdowns that could impact its data center growth. The company expects a 70% revenue increase by fiscal 2028, supported by long-term purchas...
